Niagen Bioscience Inc
NAGE · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -2.63 | -0.88 | 0.04 | -0.00 |
| FCF Yield | 0.10% | 1.46% | 2.08% | 1.01% |
| EV / EBITDA | 306.48 | 94.35 | 49.10 | 159.24 |
| Quality | ||||
| ROIC | 4.32% | 7.40% | 13.04% | 3.92% |
| Gross Margin | 65.00% | 63.42% | 62.48% | 63.49% |
| Cash Conversion Ratio | 0.81 | 0.35 | 1.56 | 1.20 |
| Growth | ||||
| Revenue 3-Year CAGR | 14.37% | 12.84% | 11.74% | 11.40% |
| Free Cash Flow Growth | -85.80% | -7.79% | 146.50% | 1,351.45% |
| Safety | ||||
| Net Debt / EBITDA | -16.11 | -10.11 | -5.60 | -14.91 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.76 | 1.00 | 1.19 | 0.89 |
| Cash Conversion Cycle | 33.93 | 25.29 | 29.49 | 60.05 |